Clinical features and outcomes of patients with diffuse unilateral subacute neuroretinitis treated with oral albendazole

Show simple item record

dc.contributor.author Souza, E. C.
dc.contributor.author Casella, AMB
dc.contributor.author Nakashima, Y.
dc.contributor.author Monteiro, MLR
dc.date.accessioned 2016-01-24T12:38:02Z
dc.date.available 2016-01-24T12:38:02Z
dc.date.issued 2005-09-01
dc.identifier http://dx.doi.org/10.1016/j.ajo.2005.03.065
dc.identifier.citation American Journal of Ophthalmology. New York: Elsevier B.V., v. 140, n. 3, p. 437-445, 2005.
dc.identifier.issn 0002-9394
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/28444
dc.description.abstract PURPOSE: To investigate the clinical features, visual function outcomes, and adverse events in patients with diffuse unilateral subacute neuroretinitis (DUSN) treated with high dose oral albendazole.DESIGN: Interventional case series.METHODS- Twelve Brazilian patients, aged 7 through 36 years, with active DUSN in the early or late clinical stage, were recruited for this study between 1999 and 2001. A small variant motile worm was found in 4 (33.3%) of these cases. All patients were treated exclusively with high-dose oral albendazole (400 mg/d) for 30 days.RESULTS: Improvement of visual acuity, visual field, and active ocular inflammatory signs was observed in all patients after 4 weeks of treatment (median follow-up: 3 years). Also, during the first weeks of treatment, evidence of worm inactivation was documented for the four patients with visible worms. No adverse drug side effects were observed in any of our cases during follow-up.CONCLUSION: High-dose oral albendazole seems to be safe and beneficial for patients with DUSN. en
dc.format.extent 437-445
dc.language.iso eng
dc.publisher Elsevier B.V.
dc.relation.ispartof American Journal of Ophthalmology
dc.rights Acesso restrito
dc.title Clinical features and outcomes of patients with diffuse unilateral subacute neuroretinitis treated with oral albendazole en
dc.type Artigo
dc.rights.license http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Fed Univ Londrina
dc.contributor.institution Universidade de São Paulo (USP)
dc.description.affiliation Universidade Federal de São Paulo, Dept Ophthalmol, São Paulo, Brazil
dc.description.affiliation Fed Univ Londrina, Dept Ophthalmol, Londrina, Parana, Brazil
dc.description.affiliation Univ São Paulo, Sch Med, Dept Ophthalmol, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Dept Ophthalmol, São Paulo, Brazil
dc.identifier.doi 10.1016/j.ajo.2005.03.065
dc.description.source Web of Science
dc.identifier.wos WOS:000231929300011



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account